Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02997800
Other study ID # ANAE-219-12
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 2012
Est. completion date January 2019

Study information

Verified date February 2020
Source Queen's University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients coming for surgery often receive opioid medications, like fentanyl, to treat pain. Opioids however have many unpleasant side effects including nausea and vomiting, itching, sedation, and decreased breathing. During laparoscopic surgery increases in heart and blood pressure are often attributed to pain. It has been shown that by treating these changes with medications such as esmolol, instead of opioids, side effects and time to discharge from hospital can be reduced. Labetalol is a drug that is similar to esmolol but may have advantages over it. It is more effective at controlling both heart rate and blood pressure and it is easier and less costly to use. This study is investigating labetalol in patients having laparoscopic gallbladder surgery and comparing it to esmolol and fentanyl. Patients will be treated with one of these drugs during surgery to control heart rate and blood pressure and the effects on time to discharge, pain scores, frequency of side effects, and narcotic requirements will be observed in the recovery room. It is thought that labetalol will be shown to be as effective as esmolol and that both drugs that minimize fentanyl will show reduced time to discharge, fewer side effects, and effective treatment of heart rate and blood pressure.


Recruitment information / eligibility

Status Completed
Enrollment 172
Est. completion date January 2019
Est. primary completion date January 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- scheduled to undergo elective ambulatory laparoscopic cholecystectomy under general anesthesia

- American Society of Anesthesiologist's Status ASA) 1-3

- able to understand and sign informed consent

Exclusion Criteria:

- known allergy to any of the study medications including beta blockers, fentanyl, acetaminophen, non-steroidal anti-inflammatories or local anesthetics

- chronic use of beta-adrenergic receptor antagonists or opioids

- conversion to open cholecystectomy

- History of renal, hepatic or cardiac failure, reactive airway disease

- Medical history that in the investigator's judgement would interfere with the protocol or assessments

- Unable to understand pain assessment

- Failure to give informed consent

- pregnant or breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Esmolol
Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of esmolol 30 mg IV (30 mg in 5 ml of normal saline). An intravenous esmolol infusion will be initiated at 5mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5mcg/kg/min each time HR or MAP >20% of baseline. An intravenous bolus of placebo (normal saline 1 ml) will be administered whenever a change to the infusion rate is made.
Labetalol
Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of labetalol 10 mg IV (10 mg in 5 ml of normal saline). Any further increases in HR or MAP >20% of baseline will be treated with intravenous boluses of labetalol 5 mg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
Fentanyl
Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of fentanyl 50 mcg IV (50 mcg in 5 ml of normal saline). Any further increases in HR or MAP >20% of baseline will be treated with intravenous boluses of fentanyl 25 mcg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
Other:
saline infusion
An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
1 ml saline infusion
Every time the infusion rate of esmolol is changed, 1 ml of normal saline will be infused.

Locations

Country Name City State
Canada Queen's University, Department of Anesthesiology Kingston Ontario

Sponsors (1)

Lead Sponsor Collaborator
Dr. Robert Tanzola

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Length of stay in the post-anesthesia care unit (PACU) time from arrival in PACU after surgery until discharge from PACU The time-frame between entry to PACU and discharge from PACU (approximately 1.5 hours).
Secondary Intraoperative Heart Rate (HR) heart rate (beats per min.) intraoperatively-from anesthesia induction to the surgery completion (wound closure) -approximately 45 min.
Secondary Intraoperative mean arterial pressure (MAP) blood pressure (mmHg) intraoperatively-from anesthesia induction to the surgery completion (wound closure)-approximately 45 min.
Secondary postoperative nausea and vomiting (PONV) in PACU incidence of nausea and vomiting The time-frame between entry to PACU and discharge from PACU (approximately 1.5 hours).
Secondary pain scores pain scores visual analogue scale (VAS) The time-frame between entry to PACU and discharge from PACU (approximately 1.5 hours).
Secondary fentanyl required total fentanyl required mcg The time-frame between entry to PACU and discharge from PACU (approximately 1.5 hours).
Secondary adverse effects Any reported adverse effects or complications The time-frame between entry to PACU and discharge from PACU (approximately 1.5 hours).
Secondary postoperative heart rate heart rate (beats per min) The time-frame between entry to PACU and discharge from PACU (approximately 1.5 hours).
Secondary postoperative mean arterial pressure (MAP) blood pressure (mmHg) The time-frame between entry to PACU and discharge from PACU (approximately 1.5 hours).
See also
  Status Clinical Trial Phase
Completed NCT03832205 - Validation of Respiratory Rate and Heart Rate Measurements by Capaciflectors Placed in Four Locations on the Chest
Completed NCT03723954 - Heart Rate Variations of Golf Fans During the 2018 the Ryder Cup
Withdrawn NCT01026961 - Safety of Phenylephrine Hydrochloride, Acetaminophen, Dimethindene Maleate Compared to Phenylephrine Hydrochloride Alone in Healthy Volunteers Phase 1/Phase 2
Completed NCT00760253 - Compare the Side Effects and Difference Awake Level of Three TCI Propofol Formula in TVOR Patients N/A
Completed NCT00380341 - Effects of Instrument-Applied Spinal Manipulative Therapy on Postureal Control and Autonomic Balance N/A
Completed NCT04179279 - Comparative Analysis of a Non-contact Respiratory and Heart Rate Monitor Vs. a Conventional Clinically Validated Reference Monitor
Completed NCT02469844 - Heart Rate Variability (HRV) Analysis in Patients With Nocturnal Epileptic Seizures
Not yet recruiting NCT00503282 - Urinary Catheter Exchange on Admission of Septic Elderly With Permanent Catheter Before Initiation of Antibiotics N/A
Completed NCT05160207 - Intubation-induced Decrease in Heart Rate as an Indicator for Intraoperative Bradycardia
Withdrawn NCT01701960 - Effect of Local Anesthetic on Hemodynamic Measures During Nasal Surgery N/A
Completed NCT03359928 - Acute Physiological and Perceptual Responses to Novel Forms of High-intensity Interval Exercise N/A
Completed NCT05600725 - Novel Cardiac Pacing to Initiate Cardiac Remodeling in Heart Failure N/A
Completed NCT05366049 - The Effect of Methods Used in Oral Antipyretic Administration on the Vital Findings of the Child With Fever N/A
Recruiting NCT05401435 - Reliability of Measuring Blood Pressure With a Smartwatch N/A
Completed NCT01638169 - The Contribution of Heels for Walking Quality Among Children With Muscular Dystrophy N/A
Completed NCT00143988 - Heart Rate and Blood Pressure Response During Exercise and Sexual Activity in Normotensive and Hypertensive Volunteers N/A
Completed NCT03131375 - Dexmedetomidine Reduces Emergence Delirium in Children Undergoing Tonsillectomy With Propofol Anesthesia Phase 2/Phase 3
Completed NCT01612130 - Valerian for Conscious Sedation in Patients Submitted to Impacted Lower Third Molars Surgery N/A
Completed NCT06095635 - Acute Influence of Resveratrol Supplementation and Beet Extract in Recovery After Exercise in Coronary Paths N/A
Not yet recruiting NCT05886153 - Verification Protocol for the Cloud DX Vitaliti Continuous Vital Signs Monitor (VERDICT-2) N/A